Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
References
Abbreviations
Hematology
Biosimilars
Global Health
PromactaⓇ - Thrombopoetin receptor agonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT03025698 (CETB115E2201)
Refractory or relapsed severe aplastic anemia
Phase 2
51
PK of eltrombopag at steady state in pediatric patients with SAA
Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS
Arm A: relapsed/refractory SAA or recurrent AA following IST for
SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag
Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag
Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent
AA after IST or previously untreated SAA
Primary CSR: 2022
Final CSR: 2025
TBD
NCT03988608 (CETB115E2202)
Refractory or relapsed severe aplastic anemia
Phase 2
20
Hematologic response rate rate up to 26 weeks of treatment
Eltrombopag 25 mg film-coated tablets
Chinese patients with refractory or relapsed severe aplastic anemia
Primary CSR: 2022
Final CSR: 2025
TBD
107 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation